CXCR1 and breast neoplasm: In basal-like breast tumours, treatment of PDGF-CC inhibitory antibody 6B3 can suppress the crosstalk between CAF and breast tumour cells, thus preventing transdifferentiation induced by tamoxifen or letrozole73.